[14C] Mass Balance Clinical Trial of Azvudine in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 22, 2024

Primary Completion Date

October 10, 2024

Study Completion Date

March 20, 2025

Conditions

Healthy

Interventions

DRUG

[14C]Azvudine suspension

A single oral dose of 3 mg/100 μCi of \[14C\]Azvudine suspension is given orally on an empty stomach.

Trial Locations (1)

Beijing Jishuitan Hospital, Beijing

All Listed Sponsors

lead

Henan Genuine Biotech Co., Ltd.

INDUSTRY

NCT07002281 - [14C] Mass Balance Clinical Trial of Azvudine in Healthy Male Subjects | Biotech Hunter | Biotech Hunter